Key facts
- This page summarizes ORBIMED ADVISORS LLC's Form 4 filing for SpringWorks Therapeutics, Inc. (SWTX).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 14 Sep 2022, 16:24.
ORBIMED ADVISORS LLC - 12 Sep 2022 Form 4 Insider Report for SpringWorks Therapeutics, Inc. (SWTX)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- SWTX
- Reported as of
- 12 Sep 2022
- Net transaction value
- -$4,919,148
- SEC form
- 4
- Accepted by SEC
- 14 Sep 2022, 16:24:34 UTC
- Prior SEC filing
- 18 Aug 2022
- Next SEC filing
- 14 Sep 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Carl L. Gordon, Member of OrbiMed Advisors LLC
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
ORBIMED ADVISORS LLC filed Form 4 for SpringWorks Therapeutics, Inc. (SWTX) on 14 Sep 2022.
Change
- Previous filing in this sequence was filed on 18 Aug 2022.
- Current net transaction value: -$4,919,148.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SWTX
transaction
Common Stock
Sale
- Transaction value
- $3,959,748
- Shares
- -123,897
- Change %
- -2.2%
- Price
- $31.96
- Shares after
- 5,629,842
- Date
- 12 Sep 2022
- Ownership
- See Footnotes
- Footnotes
- F1, F2
SWTX
transaction
Common Stock
Sale
- Transaction value
- $959,400
- Shares
- -30,000
- Change %
- -0.53%
- Price
- $31.98
- Shares after
- 5,599,842
- Date
- 12 Sep 2022
- Ownership
- See Footnotes
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
ORBIMED ADVISORS LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 2 footnotes
Footnote F1
These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI, and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI.
Footnote F2
This report on Form 4 is filed by OrbiMed Advisors and OrbiMed GP VI. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.